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Background. Data on infections associated with cerebrospinal fluid (CSF) shunts among adults are limited.
Therefore, we performed a retrospective study of shunt-associated infections in adults.
Methods. Patients aged 12 years with infections associated with CSF shunts and admitted to our institution
(University Hospital Basel, Basel, Switzerland) from January 1996 through December 2006 were included retro-
spectively. Hospital charts were reviewed, and follow-up was performed by assessment of later hospitalizations and
telephone contact with patients, their families, and general practitioners.
Results. Seventy-eight episodes of infection associated with ventriculoperitoneal shunt (65 episodes), ventri-
culoatrial shunt (7), lumboperitoneal shunt (5), and central nervous system reservoir (1) were included. Median
patient age was 50 years (range, 12–80 years); 49 (63%) of the patients were men. Most infections (48 [62%])
manifested within 1 month after shunt surgery. Fever was present in 61 episodes (78%), neck stiffness was present
in 35 (45%), and local signs of infection were present in 38 (49%). In CSF, leukocyte count was 1 cells/L65 10
in 80% of episodes, and lactate level was 11.9 mmol/L in 81% of episodes. Leukocyte counts were significantly
higher in CSF obtained by use of lumbar puncture (median leukocyte count, cells/L; ) and6573 10 Pp .001
valve puncture (median leukocyte count, cells/L; ) than in ventricular CSF (median leukocyte6484 10 Pp .016
count, cells/L). Overall, results of CSF cultures were positive in 66% of episodes (48 of 73 episodes for68.5 10
which CSF was collected), and microorganisms were isolated more often from valve puncture CSF specimens
(91% of specimens) and ventricular CSF specimens (70%) than from lumbar CSF specimens (45%). The most
prevalent organisms were coagulase-negative staphylococci (found in 37% of specimens), Staphylococcus aureus
(18%), and Propionibacterium acnes (9%). A surgical procedure was performed to treat infection in 63 (81% of
the episodes) (shunt removal in 37 episodes and shunt replacement in 26). The shunt was retained without surgery
for 15 episodes (19% of episodes). Median duration of patient follow-up was 4.6 years (range, 0.1–11.1 years),
with favorable treatment outcome in 75 (96%) of 78 cases. One of the 63 patients who underwent surgical treatment
of shunt-associated infection experienced infection relapse; of the 15 patients who received treatment with antibiotics
alone, 1 experienced infection relapse and 1 died. The 2 relapses involved rifampin-resistant coagulase-negative
staphylococci.
Conclusions. Shunt-associated infections among adults often present with nonspecific clinical signs, and affected
patients can have normal CSF leukocyte counts and lactate levels; therefore, a high index of suspicion and improved
methods are required for diagnosing shunt-associated infection.
CSF shunts significantly improve the quality of life for
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patients with hydrocephalus. Infection associated with
a CSF shunt is a severe complication with high mor-
bidity and substantial mortality [1]. The incidence of
shunt-associated infection has a range of 1%–18% [2–
5], and several independent risk factors have been iden-
tified, including previous shunt-associated infection,
Presented in part: 47th Interscience Conference of Antimicrobial Agents and
Chemotherapy, Chicago, Illinois, September 2007 (abstract K-1254).
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Table 1. Demographic and characteristics of patients with ep-
isodes of CSF shunt–associated infection.
Variable
Episodes
(n p 78)
Patient age, median years (range) 50 (12–80)
Male sex 49 (63)
Length of hospital stay, median days (range) 26 (1–100)
Underlying neurosurgical condition
Subarachnoidal bleeding 29 (37)
Intracerebral hemorrhage 19 (24)
CNS tumora 12 (15)
CNS malformationb 5 (6)
Cerebral pseudotumor 2 (3)
Subarachnoidal cyst 2 (3)
Unknown 9 (12)
Type of implanted CSF device
Ventriculoperitoneal shunt 65 (83)
Ventriculoatrial shunt 7 (9)
Lumboperitoneal shunt 5 (6)
CNS reservoir 1 (1)
Reason for shunt placement
Communicating hydrocephalus 41 (53)
Obstructive hydrocephalus 30 (38)
CSF leakage 4 (5)
Unknown 3 (4)
Route of infection acquisition
Intraoperative 56 (72)
Contiguous from another anatomical site
All 21 (27)
Head wound 11 (14)
Perforated gut 7 (9)
Sinus frontalis 2 (3)
External ventricular drainage 1 (1)
Hematogenousc 1 (1)
NOTE. Data are no. (%) of episodes, unless otherwise indicated. The per-
centages were rounded and may not add up to 100%.
a Astrocytoma (3 episodes), glioblastoma (2), neurofibroma (2), neuroblas-
toma (1), meningeoma (1), pituitary adenoma (1), neurocytoma (1), and tumor
of the inferior colliculus (1).
b Dandy Walker malformation (3 episodes), Arnold Chiari malformation (1),
and stenosis of the cerebral aqueduct (1).
c Due to Enterococcus faecalis in a patient with a ventriculoatrial shunt.
shunt revision for dysfunction, postoperative CSF leakage, ad-
vanced age, duration of the shunt placement operation, ex-
perience of the neurosurgeon, and use of a neuroendoscope
[6–8].
Organisms causing shunt-associated infections typically ad-
here to the device surface and form biofilms, which makes the
clinical and laboratory diagnosis difficult and the treatment
challenging [9, 10]. Clinical symptoms are often nonspecific,
especially when shunt-associated infections are caused by low-
virulence organisms, such as coagulase-negative staphylococci
or Propionibacterium acnes [11]. Often, only signs of intracra-
nial hypertension attributable to shunt malfunction are present,
such as headache, nausea, vomiting, and/or change in mental
state [12–15]. It is crucial to diagnose shunt-associated infection
early and accurately to be able to plan an appropriate medical
and/or surgical intervention.
Previous studies have evaluated shunt-associated infections
predominantly in the pediatric population, and only limited
data are published about infection in adults [12, 15–17]. More-
over, the antimicrobial and surgical treatment approach for
shunt-associated infections is not standardized. Current rec-
ommendations are supported mainly by case series, are ex-
trapolated from other implant-associated infections (e.g., in-
fections associated with prosthetic joints), or relay on expert
opinion.
We performed a retrospective analysis of consecutive epi-
sodes of CSF shunt–associated infection among a predomi-
nantly adult population, to describe the epidemiological, clin-
ical, laboratory, and microbiological characteristics of shunt-
associated infections and treatment outcome.
PATIENTS AND METHODS
Hospital setting. The study was conducted at the University
Hospital Basel (Basel, Switzerland), an 800-bed primary and
tertiary health care center. It is the major provider of acute
medical care for ∼300,000 area inhabitants. During the study
period, a mean of 240,000 patient-days and 23,300 hospital
admissions per year were recorded. Patients with CSF shunts
were hospitalized on the neurosurgical ward and, if required,
in a specialized intermediate care unit (8 beds), with continuous
monitoring of vital functions. During the study period, a mean
of 33 CSF shunts were inserted annually (range, 29–41 shunts
per year); none of the inserted shunts was coated with anti-
microbial agents. As preoperative antibiotic prophylaxis, a sin-
gle dose of a second-generation cephalosporin was adminis-
tered intravenously at the time of anesthesia induction. The
study was approved by the local Institutional Review and Ethics
Board.
Study population. From 1 January 1996 through 31 De-
cember 2006, all episodes of infection associated with CSF
shunts in patients aged 12 years were included. Episodes of
shunt-associated infections were identified using the microbi-
ology database and the infectious diseases consultation list. Each
episode was evaluated by 2 independent infectious diseases spe-
cialists according to predefined criteria (see below) and was
reviewed by a neurosurgeon. Excluded from the study were
patients with exclusively external CSF drainage or a subduro-
peritoneal shunt, patients whose shunt was removed before a
diagnosis of infection was determined, and patients whose
shunt-associated infection was diagnosed at another hospital.
Definitions. An infection was considered to be associated
with a CSF shunt if at least 1 of the following 2 criteria was
fulfilled (modified criteria for nosocomial infections of the Cen-
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Table 2. Clinical characteristics of patients with episodes of CSF shunt–as-
sociated infection.
Variable
Episodes
(n p 78)
Temperature 138C 61 (78)
Neurological signs and symptoms
Headache 16 (21)
Nausea 11 (14)
Neck stiffness 35 (45)
Decrease in GCS from baseline, points
Any decrease 24 (31)
1 8
2 4
3 2
4 5
5 5
No neurological signs or symptoms 28 (36)
Local signs and symptoms
Erythema 23 (29)
Local pain 15 (19)
Swelling 10 (13)
Purulent wound discharge 10 (13)
No local signs or symptoms 40 (51)
No fever or neurological or local signs or symptoms 2 (3)
Duration of symptoms before diagnosis of infection, median days (range) 5 (0–21)
Time between implantation or last surgery and manifestation of infection
!1 month 48 (62)
1–12 months 22 (28)
112 months 8 (10)
NOTE. Data are no. (%) of episodes, unless otherwise indicated. The percentages were
rounded and may not sum 100%. GCS, Glasgow Coma Scale.
ters for Disease Control and Prevention [CDC]) [18]: (1)
growth of a pathogen in the CSF, on the shunt tip, or in wounds
overlying the implanted shunt material (if the pathogen was
interpreted as relevant), or (2) fever (temperature 138C),
headache, neck stiffness, cranial nerve signs, or irritability with-
out another recognized cause; physician initiation of an ap-
propriate antimicrobial therapy for shunt-associated infection;
and a laboratory finding of CSF leukocyte count 1 cells/65 10
L, CSF total protein 10.45 g/L, a CSF-to-blood glucose ratio
!0.5, organisms seen on CSF Gram stain, or organisms found
in blood culture. The onset of infection was defined by the first
positive culture of CSF, wound swab, or shunt tip specimen,
the initiation of an appropriate antimicrobial treatment for
shunt-associated infection, or surgery at the site of the shunt
(whichever occurred first).
Data collection. Hospital charts were reviewed with a stan-
dardized case-report form to retrieve demographic, clinical,
radiographic, and laboratory data. Dual data entry by different
operators was performed, with preprogrammed consistency
checks. The following data were extracted: age, sex, need for
admission to an intensive care unit or a neurosurgical inter-
mediate care unit, length of hospital stay, underlying neuro-
surgical condition, and reason for shunt implantation (e.g.,
communicating hydrocephalus, obstructive hydrocephalus, or
CSF leakage). Shunt-specific data included date of device in-
sertion and revision (if performed) before infection, type of
CSF device (i.e., ventriculoperitoneal, ventriculoatrial, or lum-
boperitoneal shunt or CNS reservoir), and whether the device
surface was coated with antimicrobial agents. Reasons for shunt
revision before infection included shunt dysfunction, shunt tip
dislocation, or revision because of a postoperative hematoma.
Episodes were classified according to the route of infection (i.e.,
intraoperative, contiguous, or hematogenous acquisition) and
whether the manifestation of infection was early (!1 month
after shunt surgery), delayed (1–12 months), or late (112
months). The use of antimicrobial treatment and the type of
surgical procedure (i.e., no surgery, complete or partial removal
of the shunt, or a 1- or 2-stage exchange procedure) were
recorded, as was whether temporary external ventricular drain-
age was used.
Follow-up and treatment outcome. Treatment outcome
was analyzed by review of subsequent hospital admissions (if
any) and by contacting patients, their families, and general
practitioners by telephone. A relapse (treatment failure) was
defined as a shunt-associated infection that occurred within 3
months after remission of symptoms of the previous episode
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Table 3. Laboratory analysis of CSF samples from patients with
CSF shunt–associated infection.
Variable Finding
Leukocyte count
1 cells/L, no. (%) of episodes6510 48/60 (80)
Median value, cells/L (range)610 61 (0.3–5010)
Granulocyte count
 cells/L, no. (%) of episodes6110 46/60 (77)
Median value, cells/L (range)610 32 (0–3006)
Lactate level
11.9 mmol/L, no. (%) of episodes 34/42 (81)
Median value, mmol/L (range) 4 (1–14)
Total protein level
10.45 g/L, no. (%) of episodes 36/62 (58)
Median value, g/L (range) 0.8 (0.1–36)
CSF-to-blood glucose ratio
!0.5, no. (%) of episodes 16/31 (52)
Median value (range) 0.4 (0.1–1)
NOTE. Denominators indicate the episodes for which data were available.
and for which the same organism was isolated. A shunt-as-
sociated infection was defined as being new if it occurred 13
months after cure of the previous episode or culture revealed
an organism other than the organism that caused the original
infection. The status of the shunt at last contact was categorized
as (1) removed during infection and not replaced within 30
days, (2) initial infection treated and shunt still in place (with
or without additional surgery for any reason), or (3) initial
infection treated and shunt subsequently removed (including
the reason for removal). Death was attributed to shunt-asso-
ciated infection if the patient died during a clinical course
suggestive of persistent infection and no alternative specific
cause of death was detected.
Statistical analysis. Continuous variables were compared
using the Wilcoxon rank-sum test. A P value !.05 (for a 2-
sided test) was considered to be statistically significant. All cal-
culations were performed using the statistical software package
JMP, version 7 (SAS Institute). For graphic analysis, Origin
software, version 8 (OriginLab), was used.
RESULTS
Demographic and CSF shunt characteristics. During the
study period, 78 episodes of CSF shunt-associated infection
among 74 patients were identified (table 1); 4 patients devel-
oped recurrent infection. At diagnosis of infection, the median
patient age was 50 years (range, 12–80 years); 63% of infections
(49 episodes) involved male patients. The median duration of
hospital stay was 26 days (range, 1–100 days). In 14 episodes
(18%), admission to the intensive care unit for a median du-
ration of 3 days (range, 1–19 days) was needed, and in 53
episodes (68%), admission to the neurosurgical intermediate
care unit for a median of 9 days (range, 1–45 days) was needed.
The most common underlying neurosurgical condition was
subarachnoidal or intracerebral bleeding; the main reasons for
shunt insertion were communicating hydrocephalus and ob-
structive hydrocephalus (table 1). Most shunt-associated in-
fections involved ventriculoperitoneal shunts (65 infections
[83%]) and were acquired intraoperatively (56 [72%]). Before
infection onset in 25 episodes (32%), revision of the shunt site
was performed because of shunt dysfunction (20 episodes),
shunt-tip dislocation (4), or postoperative hematoma (1).
Clinical characteristics. Table 2 summarizes clinical signs
and symptoms at the time of infection diagnosis. Fever 138C
was present in 61 episodes (78%), neck stiffness was present
in 35 episodes (45%), and a decrease of Glasgow Coma Scale
was present in 24 episodes (31%), whereas headache (21%)
and nausea (14%) were less common. Local signs of infection
were present in 38 episodes (49%) and included erythema, local
pain, swelling, and/or purulent wound discharge. Only 2 epi-
sodes (3%) involved neither fever nor neurological or local
manifestations of infection; both episodes were caused by co-
agulase-negative staphylococci. Neurological signs or symptoms
were absent in 28 episodes (36%); among those episodes, the
most common pathogens were coagulase-negative staphylo-
cocci (found in 13 episodes) and Staphylococcus aureus (found
in 6 episodes).
The median duration of symptoms before hospital admission
was 5 days (range, 0–21 days). The median time between shunt
insertion or revision (whichever occurred later) and manifes-
tation of infection was 17 days (range, 0 days to 6.9 years).
Most infections occurred early (48 episodes [62%]), within a
month after shunt placement or revision, 28% (22) involved
delayed manifestation (1–12 months after surgery), and 10%
(8) involved late manifestation (112 months after surgery).
Radiological characteristics. The cranial CT scan showed
signs of shunt-associated infection in 8 (12%) of 66 episodes,
with meningeal enhancement seen in 5 episodes and brain
abscess seen in 3 episodes. Shunt-associated meningitis was
suspected in 1 (13%) of 8 episodes on the basis of cranial MRI
results. For detection of infection associated with the abdominal
part of the shunt, CT scan was more reliable than ultrasound;
with use of CT, signs of infection were seen in 10 (77%) of 13
episodes and included inflammation of fat or muscle tissue
around the shunt (in 4 episodes), thickened gut wall (2), intra-
abdominal abscess (2), intraintestinal shunt dislocation (1), or
peritoneal cyst (1). Abdominal ultrasound showed signs of in-
fection in 7 (50%) of 14 episodes, including fluid collection
around the distal shunt tip (in 4 episodes), thickened gut wall
(1), ascites (1), and peritoneal cyst (1).
Laboratory characteristics. Blood leukocyte counts were
1 cells/L in 26 episodes (33%), with a median of912 10
cells/L (range, cells/L). C-reactive pro-9 99.8 10 2.2–24 10
tein level was 15 mg/L in 57 (76%) of 75 episodes in which it
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Figure 1. Distribution of leukocytes (A), granulocytes (B), and lactate
(C) in CSF, by specimen collection site. Boxes represent the 25th and
50th percentiles, horizontal lines within the boxes indicate median values,
and whiskers indicate ranges. Numbers next to boxes denote median
values (range) for each group.
was determined, with a median value of 52 mg/L (range, 1–
302 mg/L).
Table 3 summarizes laboratory characteristics of CSF. CSF
specimens were available for laboratory analysis for 73 episodes
(94%). Specimens were collected from the cerebral ventricle
during surgery in 40 episodes (55%), by lumbar puncture in
22 episodes (30%), or by valve puncture in 11 episodes (15%).
CSF leukocyte counts were abnormal in 80% (48 of 60 episodes
in which it was determined), CSF lactate levels were abnormal
in 81% (34 of 42), CSF total protein levels were abnormal in
58% (36 of 62), and CSF-to-blood glucose ratios were abnormal
in 52% (16 of 31) of episodes.
Figure 1 shows the distribution of leukocytes, granulocytes,
and lactate level by site of the CSF collection. Leukocyte counts
were significantly higher in CSF obtained from valve puncture
( cells/L; range, cells/L; ) and6 6484 10 3–2750 10 Pp .016
lumbar CSF ( cells/L; range, cells/L;6 6573 10 1–5010 10
) than in ventricular CSF ( cells/L; range,6Pp .001 8.5 10
cells/L). Similarly, granulocyte percentage was60.3–2020 10
significantly higher in CSF collected from the shunt valve
( ) and lumbar CSF ( ) than in ventricular CSF,Pp .002 Pp .001
whereas CSF lactate levels were not statistically significantly
different. Only in 2 episodes were the results of CSF analysis
completely normal: 1 infection was caused by coagulase-neg-
ative staphylococci, and the other episode was a polymicrobial
infection.
Microbiology. The infection pathogen was determined in
71 episodes (91%) and was isolated either from swabs of wound
overlying the shunt material, culture of the shunt tip, CSF, or
blood specimens; in 7 episodes (9%), no organism was deter-
mined by culture; 5 of the 7 episodes received prior or con-
comitant antimicrobial treatment.
Table 4 shows the microbiological findings in terms of time
between shunt procedure and infection onset (i.e., early, de-
layed, or late). Overall, the most prevalent organisms were co-
agulase-negative staphylococci (in 29 [37%] of 78 episodes), S.
aureus (14 [18%]), P. acnes (7 [9%]), and viridans group strep-
tococci (3 [4%]). Gram-negative rods (enterobacteriaceae and
nonfermenters) were identified in culture in only 5 (6%) of
the 78 episodes. In 9 additional episodes involving gram-neg-
ative rods (Pseudomonas aeruginosa, Klebsiella species, Esche-
richia coli, and Serratia marcescens), other organisms were also
present; 5 of these polymicrobial infections originated from a
head wound, and 4 originated from the gut. The pathogen was
found by Gram stain of CSF sediment in 26 (38%) of 68 ep-
isodes where a Gram stain was performed. In episodes with
normal CSF leukocyte counts (12 episodes), coagulase-negative
staphylococci (8), P. acnes (1), Enterobacter cloacae (1), S. aureus
(1), and 11 organism (1) were isolated.
Figure 2 shows the rate of culture positivity by specimen
collection site. Ninety-three percent of wound swab cultures
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Table 4. Microbiological findings for episodes of CSF shunt–associated infection.
Pathogen
Overall
(n p 78)
Infection onset
Earlya
(n p 48)
Delayedb
(n p 22)
Latec
(n p 8)
Coagulase-negative staphylococcid 29 (37) 19 9 1
Staphylococcus aureusd 14 (18) 9 5 …
Propionibacterium acnes 7 (9) 5 2 …
Viridans group streptococci 3 (4) 2 1 …
Enterobacteriaceaee 3 (4) 3 … …
Nonfermentersf 2 (3) … 1 1
Enterococcus species 1 (1) … 1 …
Polymicrobialg 12 (15) 4 2 6
Culture negative 7 (9) 6 1 …
NOTE. Data are no. (%) of episodes. Percentages were rounded.
a
!1 Month after shunt surgery.
b 1–12 Months after shunt surgery.
c
112 Months after shunt surgery.
d Sixteen (55%) of 29 coagulase-negative staphylococci isolates were methicillin resistant; no S.
aureus isolate was methicillin resistant. Ten (34%) of 29 coagulase-negative staphylococci isolates
were resistant to rifampin; 6 affected patients had shunt removal without immediate replacement, 3
had 2-stage shunt replacement, and 1 had 1-stage shunt replacement. No S. aureus isolate was
rifampin resistant.
e Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae (each isolated once).
f Pseudomonas aeruginosa and Comamonas testosteroni (each isolated once).
g Nine (75%) of 12 polymicrobial infections also included gram-negative rods (P. aeruginosa, Kleb-
siella species, Serratia marcescens, E. cloacae, and E. coli), of which 5 originated from a head wound
overlying the shunt material and 4 originated from the gut.
were positive, and 78% of shunt tip cultures were positive.
Overall, CSF culture results were positive for 48 (66%) of 73
episodes. The causative pathogen was isolated more often in
CSF obtained at the shunt valve (10 [91%] of 11 episodes) and
from cerebral ventricles (28 [70%] of 40 episodes) than from
CSF obtained by lumbar puncture (10 [45%] of 22 episodes).
The rate of negative culture results correlated with prior an-
timicrobial treatment. Nine (41%) of 22 patients whose lumbar
CSF was analyzed had received prior antimicrobial treatment,
and 5 of these 9 patients had culture-negative shunt-associated
infection. Only 4 (10%) of 40 episodes for which ventricular
CSF from valve puncture was analyzed and only 1 (9%) of 11
episodes for which CSF from valve puncture was analyzed re-
ceived prior antimicrobial treatment. Despite the treatment,
culture results in all these episodes were positive.
In 53 (68%) of 78 episodes, blood samples were obtained
for culture; results were positive in 5 (83%) of 6 episodes in-
volving ventriculoatrial shunt and in 5 (11%) of 47 episodes
involving ventriculoperitoneal shunt. The most prevalent mi-
croorganisms isolated from blood cultures were coagulase-neg-
ative staphylococci (6 cultures), followed by S. aureus (3) and
Enterococcus faecalis (1).
Antimicrobial and surgical treatment. All patients re-
ceived systemic antibiotic treatment; none in this case series
was treated with intrathecal antibiotics. Median antibiotic treat-
ment duration was 18 days (range, 4–91 days). Initial antibiotic
regimen was changed in 33 episodes (42%), for reasons that
included adaptation to microbiological culture results (26 ep-
isodes), inadequate treatment response (3), allergy (2), and
change to an oral regimen (2).
A surgical procedure was performed to treat shunt-associated
infection in 63 (81%) of 78 episodes (figure 3). Surgical pro-
cedures included shunt removal without replacement within
30 days (37 [47%] of 78 episodes), 1-stage shunt replacement
(8 [10%] of 78 episodes), 2-stage shunt replacement with tem-
porary external ventricular drainage (12 [15%] of 78 episodes),
and 2-stage shunt replacement without external ventricular
drainage (6 [8%] of 78 episodes).
In 15 episodes (19%), no surgical procedure was performed
because of good clinical and laboratory response to antibiotic
treatment alone (5 episodes), initial uncertainty about the di-
agnosis of shunt-associated infection (3), the severity of the
patient’s condition (3), lack of clinical symptoms during shunt
implantation but subsequent infection diagnosis by CSF in-
vestigation (3), or a concomitant presence of a brain abscess
that led to postponement of shunt replacement (1). Infections
in which the shunt was retained and that were treated with
antibiotics only (without surgery) were either culture-negative
(5 infections) or were caused by P. acnes (4), coagluase-negative
staphylococci (3), S. aureus (1), P. aeruginosa (1), and viridans
group streptococci (1). Among these episodes, 13 infections
were acquired intraoperatively. These episodes were clinically
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Figure 2. Rate of positive culture results by specimen collection site. VA, ventriculoatrial; VP, ventriculoperitoneal.
more prominent, compared with those in the overall study
population, with fever being present in 14 episodes (93%) and
neck stiffness present in 13 (87%), whereas local signs of in-
fection were found in only 1. Treatment duration was similar
to that for the study group overall (median duration, 22 days;
range, 10–91 days), as was length of hospital stay (median
duration, 27 days; range, 4–87 days).
Outcome. Figure 3 summarizes the treatment outcome and
the status of the shunt at last follow-up. Median duration of
patient follow-up was 4.6 years (range, 0.1–11.1 years) after
onset of shunt-associated infection. Treatment outcome was
favorable in 75 (96%) of 78 episodes; treatment failure occurred
in 1 of 63 episodes with surgical treatment and in 2 of 15
episodes treated with antibiotics alone. Among the 3 patients
who experienced treatment failure, 1 patient died because of
the P. aeruginosa shunt-associated infection during the hospital
stay (see below). Two patients experienced relapse (treatment
failure) during the follow-up period. Both relapses were caused
by coagulase-negative staphylococci. In the first relapse episode,
no surgical treatment was performed. The infection was caused
by a coagulase-negative staphylococcus strain that was initially
susceptible to rifampin but that developed rifampin resistance
during a 13-week course of combined treatment with vanco-
mycin and rifampin. Relapse occurred 12 days after the dis-
continuation of antimicrobial treatment. The second relapse
episode occurred in a patient who underwent a 1-stage shunt
replacement. At that time, 2 morphotypes of coagulase-negative
staphylococci were isolated: one strain was susceptible to and
the other strain was resistant to rifampin. This patient received
treatment with vancomycin and rifampin for 18 days. The re-
lapse occurred 1 day after discontinuation of antimicrobial
treatment, and a rifampin-resistant coagulase-negative staph-
ylococcus strain was isolated.
In 4 patients, a new infection occurred in the follow-up
period; the shunt was removed during the first infection episode
for 2 patients, and a 2-stage shunt replacement with temporary
external ventricular drainage was performed for the other 2
patients. New infections occurred 5–29 months after the first
episode and were caused by different organisms than those that
caused the initial episode.
During follow-up, the shunt was removed in 12 (15%) of
the 78 episodes for various reasons. Among the patients who
underwent a surgical procedure to treat the initial shunt-as-
sociated infection, removal was performed because of shunt
dysfunction (for 5 episodes) or new infection (4). Among pa-
tients treated only with antibiotics during the initial shunt-
associated infection, all shunt removals during the follow-up
period were performed because of noninfectious reasons, in-
cluding no further need for CSF drainage, soft-tissue defect
overlying the shunt, or suspected shunt-associated infection,
the last of which was subsequently not confirmed. During the
follow-up period, 2 patients underwent an additional surgical
procedure because of shunt dysfunction.
Overall, 11 (15%) of the 74 patients died, of whom 5 died
during their hospital stay and 6 died during the follow-up
period. One patient died of a P. aeruginosa shunt-associated
infection. For this 40-year-old patient with intracerebral hem-
orrhage, no surgical treatment was performed because of refusal
by the patient’s relatives. All other in-hospital deaths were un-
related to the shunt-associated infection and included deaths
due to cardiac failure (1 patient), glioblastoma multiforme (1),
and pneumonia (2).
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Figure 3. Antimicrobial and surgical treatment strategies and treatment outcomes of CSF shunt–associated infections. During follow-up, 2 relapses
and 4 reinfections occurred. 1Removal, for noninfectious reasons. 2Relapse, coagulase-negative staphylococci, rifampin resistant. 3Death, Pseudomonas
aeruginosa infection associated with ventriculoperitoneal shunt; surgical treatment refused.
DISCUSSION
Most published studies of CSF shunt–associated infections have
involved the pediatric population [4, 6, 19]. In the present
article, we investigated the characteristics and outcomes of 78
consecutive episodes of shunt-associated infection in the adult
patient population. Similar to the findings involving children
[16, 20], the majority of shunt-associated infections in our
study occurred within the first month after shunt surgery (in
62% of episodes) and were acquired intraoperatively (72%). In
approximately one-third of patients, a shunt revision needed
for noninfectious reasons, which is a recognized independent
risk factor for infection, preceded the infection episode. Most
infected patients were admitted to the neurosurgical interme-
diate care unit (68%), and some were admitted to the intensive
care unit (18%), indicating the considerable morbidity related
to shunt-associated infections.
In contrast to native meningitis, shunt-associated infections
often presented with nonspecific clinical signs and symptoms
(e.g., fever), whereas typical neurological manifestations—such
as neck stiffness, a decrease in Glasgow Coma Scale, headache,
or nausea—were present in less than one-half of the episodes.
Remarkably, 22% of patients had no fever, and 36% showed
no neurological abnormalities. This fact reflects the nature of
implant-associated infections, which are typically caused by
low-virulence and slowly replicating organisms growing on the
shunt surface in biofilms, such as coagulase-negative staphy-
lococci, the most common cause of shunt-associated infections.
Interestingly, CSF leukocyte count and CSF lactate levels were
normal in ∼20% of episodes and can, therefore, not be used
to exclude a shunt-associated infection. A cutoff for CSF lactate
of 4 mmol/L was found to best identify patients with post-
operative meningitis [21]. However, in the cited study [21],
only 1 patient had a CSF shunt in place. If we had applied this
cutoff to our patient group, almost one-half of shunt-associated
infections would have been missed. Therefore, we used a lower
cutoff of CSF lactate in our study (1.9 mmol/L). The specificity
of this value needs to be evaluated in studies that also include
patients without CSF shunt-associated infection.
Of note, CSF leukocyte count and granulocyte percentage
strongly varied by CSF sampling site and were significantly
higher in the CSF obtained through lumbar and valve puncture
than in the ventricular CSF. These findings may reflect differ-
ences in inflammation in the ventricular system or in the CSF
flow in patients with hydrocephalus. An alternative explanation
could be that lumbar puncture and valve puncture were per-
formed among patients with advanced shunt-associated infec-
tion who presented with fever, whereas ventricular CSF was
sampled during shunt surgery at an earlier stage of infection
in patients with only local manifestations of infection. Pro-
spective studies with concomitant CSF sampling from different
sites are needed to further evaluate differences in CSF values
from various collection sites.
In our study, 66% of episodes had positive CSF culture re-
sults, and 38% had positive CSF Gram stain results. The CSF
culture positivity depended on the collection site and was high-
est for CSF obtained from valve puncture (91%), potentially
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reflecting the high microbial density in biofilms at the site of
infection, which is also supported by the high rate of positive
shunt tip cultures (78%). Interestingly, lumbar CSF yielded the
pathogen in only 45% of episodes, which may be partially
explained by preceding antimicrobial treatment; 5 of 12 neg-
ative results of lumbar CSF culture were obtained from patients
receiving antibiotics before CSF sampling. The high rate of
positive wound swab culture results (93%) may represent a
selection bias, because wound swab specimens were typically
obtained only from patients with clinically evident wound
infection.
The most common pathogens in our study were staphylo-
cocci and P. acnes. This is in accordance with other studies,
which have found the most common etiologic agents to be
coagulase-negative staphylococci (in 47%–65% of episodes), S.
aureus (12%–29%), gram-negative rods (6%–20%), and P. ac-
nes (1%–14%) [4, 8, 11, 12, 17, 22, 23]. The spectrum of the
microorganisms suggests that patient skin flora is an important
source of shunt-associated infections [22]. Other means of in-
fection have also been discussed, such as direct inoculation of
shunt material from the surgeon or the environment in the
operating room, hematogenous spread from a distant focus
(especially with ventriculoatrial shunts), or contiguous infec-
tion from wounds or perforated gut [2, 24, 25]. Polymicrobial
infections were reported mainly when the shunt tip perforated
the gut [22, 25]. In our study, most polymicrobial infections
presented late and were caused by gut perforation or occurred
in patients with head wounds overlying the shunt.
To date, only 1 prospective randomized trial has investigated
the outcome of 3 different surgical treatment strategies among
30 children, all receiving antimicrobial treatment [26]. In that
study, outcome was favorable in patients with 1-stage or 2-
stage shunt replacement with temporary external ventricular
drainage (cure rates, 90% and 100%, respectively), whereas
without shunt removal, the cure rate was only 30%. Several
retrospective analyses underlined these findings [13, 15, 27, 28].
Therefore, a 2- or 1-stage shunt replacement with concomitant
administration of intravenous antibiotics is the current rec-
ommended treatment strategy. In 1 study, temporary exter-
nalization of only the peritoneal shunt catheter with subsequent
replacement was effective in 10 (91%) of 11 patients [29].
A conservative management without surgical intervention
was investigated in infection associated with ventriculoperito-
neal shunt; this study included 43 shunt-associated infections
caused by coagulase-negative staphylococci [30]. In this ob-
servational study, the success rate was 93%. Similar results were
achieved among patients with shunt-associated infections
caused by P. acnes [11]. In our study, 15 shunt-associated in-
fections (19%) were treated conservatively. In this treatment
group, 1 relapse and 1 death attributable to shunt-associated
infection occurred. The relapse was caused by a coagulase-
negative staphylococcus that was resistant to rifampin, a crucial
antibiotic for treating device-associated staphylococcal infec-
tions. Another treatment failure was experienced by a patient
with a 1-stage shunt exchange and was also caused by a rif-
ampin-resistant coagulase-negative staphylococcus. No treat-
ment failure was observed in the 2-stage shunt exchange group,
with or without temporary external ventricular drainage. Over-
all, treatment outcome in our study was favorable in 75 (96%)
of 78 episodes.
This study has limitations inherent to its retrospective design.
First, diagnostic and therapeutic procedures did not follow a
predefined scheme, which may have biased the interpretation
of the results—in particular, the value of different diagnostic
tests performed. For example, CSF was collected from different
sites, which makes interpretation of sensitivity and specificity
difficult. Second, because of the nature of CSF shunt–associated
infections with different shunt types and operative procedures,
significant associations of one or a group of variables were
difficult to find. Third, the sensitivity and specificity of indi-
vidual laboratory tests could not be determined, because the
control group without shunt-associated infection was not eval-
uated for comparison. Nevertheless, we believe that our mainly
descriptive analysis is valuable and has several strengths. This
analysis covers an 11-year period and includes a median follow-
up of 4.6 years. Although this was done partly in an indirect
way—by chart review from rehospitalizations or by contacting
patients or their physicians—we were able to estimate the long-
term prognosis. A second strength is the in-depth standardized
approach that we undertook to investigate all episodes, which
demonstrated a detailed picture of shunt-associated infections
in predominantly adult neurosurgical patients.
In summary, patients with CSF shunt–associated infections
often presented early after shunt placement or revision and
with nonspecific clinical signs and symptoms (especially fever)
and normal CSF values. Therefore, a high clinical suspicion of
CSF shunt–associated infection is needed also in the absence
of neurological signs and symptoms. CSF values and culture
positivity depended on the CSF collection site; according to
our results, it is preferable to collect CSF from the valve, where
leukocyte counts and the rate of culture positivity were highest.
Shunt-associated infections were caused predominantly by
gram-positive skin flora. In selected patients (those with in-
fections due to low-virulence microorganisms that are suscep-
tible to biofilm-active antibiotics, such as rifampin), antibiotic
therapy without surgical treatment of shunt-associated infec-
tion may be an effective treatment modality. Both treatment
failures in our study—one in the 1-stage shunt exchange group
and the other in the antibiotic-only treatment group—involved
coagulase-negative staphylococci with resistance to rifampin, a
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crucial antibiotic for the treatment of device-associated staph-
ylococcal infections.
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